{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:34:15Z","timestamp":1783578855491,"version":"3.55.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T00:00:00Z","timestamp":1774137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006107","name":"Gil Medical Center, Gachon University","doi-asserted-by":"publisher","award":["FRD2022-05-02"],"award-info":[{"award-number":["FRD2022-05-02"]}],"id":[{"id":"10.13039\/501100006107","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006107","name":"Gil Medical Center, Gachon University","doi-asserted-by":"publisher","award":["FRD2023-09-02"],"award-info":[{"award-number":["FRD2023-09-02"]}],"id":[{"id":"10.13039\/501100006107","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002631","name":"Gachon University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002631","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008212","name":"College of Medicine, Drexel University","doi-asserted-by":"publisher","award":["202509500001"],"award-info":[{"award-number":["202509500001"]}],"id":[{"id":"10.13039\/100008212","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jlr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Lipid Research"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jlr.2026.101024","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:08:39Z","timestamp":1774310919000},"page":"101024","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Fenofibrate plus statin and ASCVD risk by triglyceride-rich lipoprotein cholesterol in 70,000 patients"],"prefix":"10.1016","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8802-268X","authenticated-orcid":false,"given":"Youngwoo","family":"Jang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Whi","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Ryong","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwang Kon","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00f8rge G.","family":"Nordestgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7315-7557","authenticated-orcid":false,"given":"Seung Hwan","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jlr.2026.101024_bib1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.jlr.2026.101024_bib2","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.jlr.2026.101024_bib3","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.jacc.2005.02.052","article-title":"Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia","volume":"45","author":"Koh","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.jlr.2026.101024_bib4","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1161\/01.HYP.0000187900.36455.4c","article-title":"Beneficial vascular and metabolic effects of Peroxisome proliferator-activated Receptor-\u03b1 activators","volume":"46","author":"Han","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.jlr.2026.101024_bib5","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1161\/CIRCULATIONAHA.113.003008","article-title":"Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation","volume":"128","author":"Varbo","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jlr.2026.101024_bib6","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jlr.2026.101024_bib7","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1373\/clinchem.2014.234146","article-title":"Extreme nonfasting remnant cholesterol vs extreme LDL cholesterol as contributors to cardiovascular disease and all-cause mortality in 90000 individuals from the general population","volume":"61","author":"Varbo","year":"2015","journal-title":"Clin. Chem."},{"key":"10.1016\/j.jlr.2026.101024_bib8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4070\/kcj.2016.46.2.135","article-title":"Hypertriglyceridemia and cardiovascular diseases: revisited","volume":"46","author":"Han","year":"2016","journal-title":"Korean Circ. J."},{"key":"10.1016\/j.jlr.2026.101024_bib9","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-Rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ. Res."},{"key":"10.1016\/j.jlr.2026.101024_bib10","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1016\/j.jacc.2020.09.610","article-title":"VLDL cholesterol accounts for one-half of the risk of myocardial infarction associated with apoB-Containing lipoproteins","volume":"76","author":"Balling","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.jlr.2026.101024_bib11","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/s13063-020-04291-5","volume":"21","author":"Kwon","year":"2020","journal-title":"Trials"},{"key":"10.1016\/j.jlr.2026.101024_bib12","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1253\/circj.CJ-20-1037","article-title":"New trends in dyslipidemia treatment","volume":"85","author":"Jang","year":"2020","journal-title":"Circ. J."},{"key":"10.1016\/j.jlr.2026.101024_bib13","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1093\/eurheartj\/ehab293","article-title":"Directly measured vs. calculated remnant cholesterol identifies additional overlooked individuals in the general population at higher risk of myocardial infarction","volume":"42","author":"Varbo","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.jlr.2026.101024_bib14","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/j.jacc.2022.03.384","article-title":"Elevated remnant cholesterol reclassifies risk of ischemic heart disease and myocardial infarction","volume":"79","author":"Doi","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.jlr.2026.101024_bib15","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1093\/eurheartj\/ehab705","article-title":"Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: a cohort-based study","volume":"43","author":"Wadstrom","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.jlr.2026.101024_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2023.05.010","article-title":"Dual elevated remnant cholesterol and C-reactive protein in myocardial infarction, atherosclerotic cardiovascular disease, and mortality","volume":"379","author":"Doi","year":"2023","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jlr.2026.101024_bib17","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/eurheartj\/ehac822","article-title":"Elevated remnant cholesterol, plasma triglycerides, and cardiovascular and non-cardiovascular mortality","volume":"44","author":"Wadstrom","year":"2023","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.jlr.2026.101024_bib18","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1093\/eurheartj\/ehw152","volume":"37","author":"Nordestgaard","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.jlr.2026.101024_bib19","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002765","article-title":"Remnant Lipoprotein cholesterol and incident coronary heart disease: the Jackson heart and Framingham offspring cohort studies","volume":"5","author":"Joshi","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.jlr.2026.101024_bib20","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2023.38.e295","article-title":"Triglyceride-Rich lipoproteins and remnant cholesterol in cardiovascular disease","volume":"38","author":"Heo","year":"2023","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.jlr.2026.101024_bib21","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jlr.2026.101024_bib22","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jlr.2026.101024_bib23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","article-title":"Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease","volume":"102","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jlr.2026.101024_bib24","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jlr.2026.101024_bib25","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","article-title":"Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis","volume":"375","author":"Jun","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jlr.2026.101024_bib26","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Group","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jlr.2026.101024_bib27","first-page":"e15","article-title":"Cohort profile: the national health Insurance service-national sample cohort (NHIS-NSC), South Korea","volume":"46","author":"Lee","year":"2017","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.jlr.2026.101024_bib28","doi-asserted-by":"crossref","first-page":"754","DOI":"10.4070\/kcj.2020.0171","article-title":"Cardiovascular research using the Korean national health information database","volume":"50","author":"Choi","year":"2020","journal-title":"Korean Circ. J."},{"key":"10.1016\/j.jlr.2026.101024_bib29","doi-asserted-by":"crossref","first-page":"313","DOI":"10.4070\/kcj.2022.0231","article-title":"Epidemiology of PAH in Korea: an analysis of the National Health Insurance Data, 2002-2018","volume":"53","author":"Jang","year":"2023","journal-title":"Korean Circ. J."},{"key":"10.1016\/j.jlr.2026.101024_bib30","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12933-022-01667-6","article-title":"Remnant cholesterol and the risk of cardiovascular disease in type 2 diabetes: a nationwide longitudinal cohort study","volume":"21","author":"Huh","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.jlr.2026.101024_bib31","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2337\/dc22-1550","article-title":"Remnant cholesterol is an independent predictor of type 2 diabetes: a nationwide population-based cohort Study","volume":"46","author":"Huh","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jlr.2026.101024_bib32","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin. Chem."},{"key":"10.1016\/j.jlr.2026.101024_bib33","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1001\/jama.2013.280532","article-title":"Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile","volume":"310","author":"Martin","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jlr.2026.101024_bib34","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2023.38.e145","article-title":"Comparison of newly proposed LDL-Cholesterol estimation equations","volume":"38","author":"Jeong","year":"2023","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.jlr.2026.101024_bib35","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.2337\/dc19-2095","article-title":"Underweight increases the risk of end-stage renal diseases for type 2 diabetes in Korean population: data from the National Health Insurance Service Health checkups 2009-2017","volume":"43","author":"Kim","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jlr.2026.101024_bib36","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1253\/circj.CJ-17-1113","article-title":"Routine indwelling urethral catheterization in acute heart failure patients is associated with increased urinary tract complications without improved heart failure outcomes","volume":"82","author":"Jang","year":"2018","journal-title":"Circ. J."},{"key":"10.1016\/j.jlr.2026.101024_bib37","volume":"10","author":"Jang","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jlr.2026.101024_bib38","article-title":"Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study","volume":"366","author":"Kim","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jlr.2026.101024_bib39","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.2337\/dc20-1533","article-title":"Fenofibrate use is associated with lower mortality and fewer cardiovascular events in patients with diabetes: results of 10,114 patients from the Korean national health insurance service cohort","volume":"44","author":"Jo","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jlr.2026.101024_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155327","article-title":"Fenofibrate add-on to statin treatment is associated with low all-cause death and cardiovascular disease in the general population with high triglyceride levels","volume":"137","author":"Kim","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.jlr.2026.101024_bib41","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jlr.2026.101024_bib42","doi-asserted-by":"crossref","first-page":"521","DOI":"10.5551\/jat.44412","article-title":"Efficacy and safety of pemafibrate versus fenofibrate in patients with high triglyceride and low HDL cholesterol levels: a multicenter, Placebo-Controlled, Double-Blind, randomized trial","volume":"25","author":"Arai","year":"2018","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/j.jlr.2026.101024_bib43","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12933-017-0602-y","article-title":"Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia","volume":"16","author":"Fruchart","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.jlr.2026.101024_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.120555","article-title":"Not all fibrates are made equal: learning from biology and clinical trials","volume":"411","author":"Zambon","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jlr.2026.101024_bib45","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jlr.2026.101024_bib46","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3803\/EnM.2025.2691","article-title":"Innovative lipid-lowering strategies: RNA-Based, small molecule, and protein-based therapies","volume":"40","author":"Jang","year":"2025","journal-title":"Endocrinol. Metab. (Seoul)"},{"key":"10.1016\/j.jlr.2026.101024_bib47","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12944-017-0519-1","article-title":"Lipid management in India: a nationwide, cross-sectional physician survey","volume":"16","author":"Wander","year":"2017","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.jlr.2026.101024_bib48","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1111\/dom.13372","article-title":"Lipid-lowering medication is associated with decreased risk of diabetic retinopathy and the need for treatment in patients with type 2 diabetes: a real-world observational analysis of a health claims database","volume":"20","author":"Kawasaki","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.jlr.2026.101024_bib49","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: executive summary: a report of the American college of Cardiology\/American Heart Association task force on clinical practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Journal of Lipid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022227526000507?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022227526000507?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:06:50Z","timestamp":1779923210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022227526000507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0022227526000507"],"URL":"https:\/\/doi.org\/10.1016\/j.jlr.2026.101024","relation":{},"ISSN":["0022-2275"],"issn-type":[{"value":"0022-2275","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fenofibrate plus statin and ASCVD risk by triglyceride-rich lipoprotein cholesterol in 70,000 patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Lipid Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jlr.2026.101024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"101024"}}